Sintilimab, Pegaspargase and Anlotinib for Stage IV Natural Killer /T-cell Lymphoma

NCT04004572 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

37

Enrollment

OTHER

Sponsor class

Conditions

Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type

Interventions

DRUG: LEAP regimen

Sponsor

Rong Tao